Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models

Melanoma is a recalcitrant disease. Melanoma patients with the BRAF-V600E mutation have been treated with the drug vemurafenib (VEM) which targets this mutation. However, we previously showed that VEM is not very effective against a BRAF-V600E melanoma mutant in a patient-derived orthotopic xenograf...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Kawaguchi, Kei, Igarashi, Kentaro, Li, Shukuan, Han, Qinghong, Tan, Yuying, Miyake, Kentaro, Kiyuna, Tasuku, Miyake, Masuyo, Murakami, Takashi, Chmielowski, Bartosz, Nelson, Scott D., Russell, Tara A., Dry, Sarah M., Li, Yunfeng, Unno, Michiaki, Eilber, Fritz C., Hoffman, Robert M.
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2017
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5787523/
https://ncbi.nlm.nih.gov/pubmed/29416666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23185
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items